Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioCryst Pharmaceuticals, Inc.
BioCryst initiates intravenous peramivir phase I trial for influenza
April 8th, 2006
BioCryst Pharmaceuticals, Inc., (BCRX) has initiated a phase I clinical trial of peramivir, the company's lead influenza neuraminidase inhibitor, to determine the pharmacokinetics and safety of single and multiple doses of an intravenous (IV) formulation of the drug in healthy volunteers. This double-blind, randomized, dose-escalating study of peramivir is being conducted in association with the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health (NIH). The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland, under the direction of John Beigel, MD, of the Department of Critical Care Medicine at the...
Source: Law & Health Weekly (2006-04-08)
|
